Co-Diagnostics, Inc. to Present at 21st Annual Rodman & Renshaw Global Investment Conference Sept 8-10, 2019
28 August 2019 - 8:30PM
Co-Diagnostics, Inc.
(Nasdaq: CODX), a molecular
diagnostics company with a unique, patented platform for the
development of molecular diagnostic tests, announced today that it
will be featured as a presenting company at the 21st Annual Rodman
and Renshaw Global Investment Conference on September 8-10, 2019 at
the Lotte New York Palace Hotel in New York City.
The conference is sponsored by H.C. Wainwright
& Co., LLC, who initiated equity research coverage on the
Company in Q2 2019. Dwight Egan, CEO of Co-Diagnostics, will
provide an overview of the Company’s business, progress in India
and other markets, and future revenue initiatives during the live
presentation, and will be available to participate in one-on-one
meetings with investors who are registered to attend the
conference.
If you are an institutional investor and would
like to attend the Company's presentation, please click on the
following link (www.rodmanevents.com) to register for the
conference. Once your registration is confirmed, you will be
prompted to log into the conference website to request a one-on-one
meeting with the Company.
Event: Co-Diagnostics Inc Presentation
Date: Monday, September 9, 2019
Time: 4:40 p.m. EDT
Location: Adams, 4th Floor; Lotte New York
Palace Hotel
A webcast recording of the presentation will be
found here and archived for 90 days following the event.
About Co-Diagnostics,
Inc.:Co-Diagnostics, Inc., a Utah corporation, is a
molecular diagnostics company that develops, manufactures and
markets a new, state-of-the-art diagnostics technology. The
Company’s technology is utilized for tests that are designed using
the detection and/or analysis of nucleic acid molecules (DNA or
RNA). The Company also uses its proprietary technology to design
specific tests to locate genetic markers for use in industries
other than infectious disease and license the use of those tests to
specific customers.
Forward-Looking Statements:
This press release contains
forward-looking statements. Forward-looking statements can be
identified by words such as "believes," "expects," "estimates,"
"intends," "may," "plans," "will" and similar expressions, or the
negative of these words. Such forward-looking statements are based
on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions.
Forward-looking statements in this release include statements
regarding the (i) use of funding proceeds, (ii) expansion of
product distribution, (iii) acceleration of initiatives in liquid
biopsy and SNP detection, (iv) use of the Company’s liquid biopsy
tests by laboratories, (v) capital resources and runway needed to
advance the Company’s products and markets, (vi) increased sales in
the near-term, (vii) flexibility in managing the Company’s balance
sheet, (viii) anticipation of business expansion, and (ix) benefits
in research and worldwide accessibility of the CoPrimer technology
and its cost-saving and scientific advantages. Forward-looking
statements are subject to inherent uncertainties, risks and changes
in circumstances. Actual results may differ materially from
those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities
laws.
Company
Contact:
Andrew
Benson
Head of Investor
Relations
+1
801-438-1036
investors@codiagnostics.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Apr 2024 to May 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From May 2023 to May 2024